Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of knockout of and pathogenic mutations in HNRNPH2 on gene expression in human iPSC-derived neurons

ABSTRACT: To investigate the effect of knockout of and pathogenic mutatations in HNRNPH2, we generated human iPSC lines in which endogenous HNRNPH2 has been knocked out, or 3 pathogenic mutations (R206W, R206Q, and P209L) have been knocked into the endogenous HNRNPH2 using CRISPR Cas-9.

ORGANISM(S): Homo sapiens

PROVIDER: GSE226525 | GEO | 2023/07/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of knockout of and pathogenic mutations in Hnrnph2 on gene expression in mouse cortex

Project description:To investigate the effect of knockout of and pathogenic mutatations in Hnrnph2, we generated mouse lines in which endogenous Hnrnph2 has been knocked out, or 2 pathogenic mutations (R206W, P209L) have been knocked into the endogenous Hnrnph2 using CRISPR Cas-9.

2023-07-19 | GSE226526 | GEO

Effect of knockout of and pathogenic mutations in HNRNPH2 on gene expression in human iPSC-derived neurons

Project description:Effect of knockout of and pathogenic mutations in HNRNPH2 on gene expression in human iPSC-derived neurons

| PRJNA940479 | ENA

Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder

Project description:Mutations in HNRNPH2 are associated with an X-linked disorder characterized by developmental delay, intellectual disability, motor and gait disturbances, and seizures. Murine models that reproduce key clinical features of HNRNPH2-related neurodevelopmental disorder suggest that it may result from a toxic gain of function of the mutant protein or a complex loss of normal HNRNPH2 function with impaired compensation by its homolog, HNRNPH1. In this study, we tested gapmer antisense oligonucleotides (ASOs) that target murine Hnrnph2 in a non-allele-specific manner. The lead ASO reduced Hnrnph2 mRNA and protein levels while inducing compensatory upregulation of Hnrnph1 in both WT and Hnrnph2 mutant mouse brains. A single intracerebroventricular injection of the Hnrnph2 ASO into neonatal mutant Hnrnph2 mice rescued molecular and audiogenic seizure phenotypes and improved motor and cognitive functions. ASO treatment at the juvenile stage also rescued audiogenic seizures and motor deficits. In contrast, Hnrnph2 ASO administration did not improve survival, body weight, or hydrocephalus. In human iPSC-derived neurons, a human-specific HNRNPH2 research ASO reduced HNRNPH2 and upregulated HNRNPH1 mRNA levels.

2025-11-17 | GSE310115 | GEO

Effect of knockout of and pathogenic mutations in Hnrnph2 on gene expression in mouse cortex

Project description:Effect of knockout of and pathogenic mutations in Hnrnph2 on gene expression in mouse cortex

| PRJNA940478 | ENA

Effect of knockout of and pathogenic mutations in HNRNPH2 on gene expression in human and mouse

Project description:Effect of knockout of and pathogenic mutations in HNRNPH2 on gene expression in human and mouse

| PRJNA940476 | ENA

HNRNPH2 variant linked to intellectual disability disrupts myelination by impairing oligodendrocyte differentiation

Project description:Mutations in heterogeneous nuclear ribonucleoprotein H2 (HNRNPH2) lead to an X-linked neurodevelopmental disorders (NDDs) characterized by abnormal brain development and cognitive impairments. However, the underlying cellular and molecular mechanisms remain poorly understood. Here, we report that mice carrying the homologous P213L point mutation exhibit cognitive deficits and behavioral abnormalities resembling intellectual disability (ID). Notably, Hnrnph2P213L mice exhibit significant myelination defects, primarily due to impaired differentiation of oligodendrocyte progenitor cells. Mechanistically, the P213L mutation downregulates myelination-related genes by disrupting the interaction between hnRNPH2 and its target transcripts. Moreover, the myelin-enhancing drug benztropine rescues myelination, restores myelin-related gene expression and ameliorates cognitive deficits, highlighting the role of hnRNPH2 P213L-induced myelin abnormalities in the pathogenesis of ID. This study uncovers a crucial mechanistic link between myelin dysfunction and ID, providing potentially therapeutic ways for X-linked NDDs.

2026-01-01 | GSE313803 | GEO

Pathogenic PPP2R5D variants alters the transcriptome of patient iPSC-derived glutamatergic neurons

Project description:The pathogenic PPP2R5D E198K and E420K variant alters the transcriptome of patient iPSC-derived cortical neurons

2025-05-19 | GSE266958 | GEO

Precise Gene Editing of Pathogenic Lamin A Mutations Corrects Cardiac Disease

Project description:Mutations in the lamin A (LMNA) gene, which encodes the lamin A and C proteins, cause severe human diseases collectively known as laminopathies. These conditions are often devastating and lack effective therapies. In this study, we developed precise base editing (BE) strategies targeting the human LMNA gene variants L35P and R249Q, which cause Congenital Muscular Dystrophy (CMD) and Dilated Cardiomyopathy with Conduction Defects (DCM-CD), respectively. Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) carrying the R249Q mutation displayed nuclear aberrations, DNA damage, and abnormal Ca2+ transients. Similarly, L35P iPSC-CMs exhibited abnormal contraction, DNA damage, and reduced lamin A/C protein expression. We also generated novel “humanized” mouse models carrying these pathogenic human mutations. R249Q homozygous mice exhibited cardiac conduction abnormalities, cardiac arrhythmias, and premature death. Mice with the homozygous L35P mutation displayed severe muscle-wasting and reduced lifespan, while heterozygous L35P mice displayed dilated cardiomyopathy (DCM). We developed an adenine base editing (ABE) approach for correcting the R249Q mutation and a cytosine base editing (CBE) strategy for the L35P variant. Precise correction of these mutations in iPSC-CMs successfully rescued all of the in vitro abnormalities. Furthermore, delivery of the BE components using adeno-associated virus (AAV) prevented the pathological phenotypes and extended longevity of mice carrying the LMNA L35P and the R249Q mutations. These results demonstrate the efficacy of ABE and CBE in correcting pathogenic LMNA mutations that cause cardiac disease, highlighting BE as a promising therapeutic approach for human laminopathies.

2025-09-23 | GSE308777 | GEO